New drug RO7875913 tested in healthy volunteers for first time

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General: * Agreement to adhere to the contraception requirements Part A: * Body weight \> 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg/m\^2) Part B: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Agreement to provide bone marrow biopsy and aspirate samples Exclusion Criteria: General: * Treatment with any vaccine within 4 weeks prior to initiation of study drug, or vaccination scheduled to occur during the study * History or current cardiovascular or pulmonary disease that may limit the ability to respond to systemic infusion/injection reactions * Positive test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen * History of any malignancy * Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study * History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders * Known allergy or hypersensitivity to any component of the RO7875913 formulation Part A: * Treatment with investigational biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug * Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug * Clinically apparent or familial history of autoimmune disease Part B: * Treatment with any systemic chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment * Treatment with any immunosuppressive medication within 2 weeks prior to first dose of study treatment * Absolute plasma cell count exceeding 500/mL or 5% of the peripheral blood white cells